Announcements

Removal of Component(s) - RXDX, JUNO, BIVV

February 6, 2018

LifeSci Biotechnology Clinical Trials Index

LifeSci Biotechnoloogy Products Index

Removal of Component(s) – RXDX, JUNO, BIVV

2/6/2018

Effective at the market close on Thursday, February 8, 2018, RXDX and JUNO will be removed from the LifeSci Biotechnology Clinical Trials Index and their combined values will be redistributed to the remaining index components based on their weights.

On 12/22/2017, Ignyta (RXDX) announced that it will be acquired by Roche for $27 per share in cash.
On 1/22/2018, Juno Therapeutics (JUNO) announced that it will be acquired by Celgene for $87 per share in cash.

Effective at the market close on Thursday, February 8, 2018, BIVV will be removed from the LifeSci Biotechnology Products Index and its value will be redistributed to the remaining index components based on their weights.

On 1/22/2018, Bioverativ (BIVV) announced that it will be acquired by Sanofi for $105 per share in cash.